Back to results
US 9,040,577 B2Granted
Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same
AssigneeNeuroDerm, Ltd.
InventorsOron Yacoby-Zeevi, Mara Nemas
Life of this patent
Estimating the term…
Abstract
Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Claims21
A pharmaceutically acceptable liquid composition comprising:
- (a) active components comprising:
- (i) about 2% to about 12% by weight levodopa;
- and
- (ii) carbidopa;
- and
- (b) about 5% to about 30% by weight arginine, meglumine, or a combination thereof wherein the liquid composition has a pH of about 9.1 to about 9.8 at 25° C.
3 more elements
A pharmaceutically acceptable liquid composition comprising:
- (a) about 4% to about 7% by weight levodopa;
- (b) about 0.5% to about 3% by weight carbidopa;
- and
- (c) about 9% to about 16% by weight arginine and/or meglumine, wherein said composition has a pH of about 9.1 to about 9.8 at 25° C.
1 more element
Dependencies are inferred from the claim text.